Hyperthermic Extracorporeal Applied Tumor Therapy for Six Cycles for Recurrent Metastatic Peritoneal Serous Papillary Carcinoma

Abstract

An elderly female with failed third-line peritoneal serous papillary carcinoma with metastasis (ovarian cancer) was treated by our proprietary method of whole-body hyperthermia-a recirculating extracorporeal circuit at 42°C for 120 minutes. She received six cycles, 28 days apart. Five index lesions were measured prior to and after each treatment. Results showed stable disease with reduced standard uptake volume. She then restarted six cycles of a previously failed chemotherapy, resulting in no evidence of disease for nine months; she survived for 27 months. Using our technology, the patient experienced an improvement in the quality of life and an increase in survival.

Hyperthermic Extracorporeal Applied Tumor Therapy (HEATT®) in Hospice Eligible Cancer Patients

“…Whole body, veno-venous perfusion-induced systemic hyperthermia is a unique, reliable delivery system that achieves homogeneous tissue heating to 42° and has consistently shown noteworthy, anti-neoplastic effects. Perfusion-induced systemic hyperthermia or HEATT® has the potential to slow or destroy cancer growth and metastasis [13]. Topical or surface heating cannot attain the internal organ temperature necessary to reach the required therapeutic target temperature (42°C for 120 minutes) without sustaining signi cant damage to the outer conductive tissues (skin and muscle tissue).…”

“…VV-PISH in general, and HEATT® speci cally, e ciently supply a stable thermal dose (41.8 ± 0.8°C for 120 minutes) to visceral, cranial, and thoracic organs, as well as peripheral tissues like skeletal muscle and bone marrow [13]. Multiple designated temperature monitoring points and average body temperature are used in real-time as feedback control, preventing prolonged periods in elevated or insu ciently heated temperature ranges, and serum solute maintenance and control further limit the risk of hemodynamic instability [19].…”